Evolent Health, Inc.

NYSE:EVH

Medical - Healthcare Information Services

Healthcare
$3.93 -6.00%

-$0.28 today

Market cap
$442.05M
Beta
0.83
P/E (TTM)
-1.0
EPS (TTM)
-$4.44
52W Low $2.10High $12.07

Volume 3.10M

Average 2.78M

EVH Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Evolent Health, Inc.NYSE: EVH

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $434.33M rose 13.9% year over year, ahead of the -20.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.

Context

  • Cost of revenue amounted to 84.9% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +13.9% holds above the trailing-twelve-month pace of -20.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$434.33M+4.3% QoQ
Last fiscal yearDec 2025
$1.59B-27.2% YoY
LTMMar 2026
$1.62B-20.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.9%——
1 year-27.2%——
3-year CAGR+15.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
1.59B USD
Year-over-year change
-27.2%
4-year CAGR
+24.7%

Cost of Revenue vs competitors

How EVH compares with its peers on the latest reported figures

  • EVH's LTM Mar 2026 cost of revenue of $1.62B is the 2nd highest of the 11 companies compared; the peer median is $53.97M.
  • Its year-over-year change of -20.2% is the 8th highest of 9, against a peer median of +16.2%.
  • Cost of revenue amounts to 85.9% of revenue for EVH, versus a peer median of 43.0%.
EVH Competitors Peer median
Cost of Revenue for EVH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMNAMN Healthcare Services, Inc.LTM Mar 2026$2.47B +21.6%-17.8%72.4%
EVHEvolent Health, Inc.LTM Mar 2026$1.62B -20.2%+15.4%85.9%
NUTXNutex Health, Inc.LTM Mar 2026$462.28M +44.5%+28.3%52.5%
MYGNMyriad Genetics, Inc.LTM Mar 2026$249M -0.1%+7.1%30.0%
HSTMHealthStream, Inc.LTM Mar 2026$109.48M +10.8%+5.6%35.1%
PSNLPersonalis, Inc.LTM Mar 2026$55.67M -2.6%+1.4%86.3%
BFLYButterfly Network, Inc.LTM Mar 2026$52.28M +55.2%+15.2%50.8%
MGTXMeiraGTx Holdings plcLTM Mar 2026$6.67M -73.5%—8.4%
KURAKura Oncology, Inc.LTM Mar 2026$3.83M +1795.5%—5.3%
REPLReplimune Group, Inc.LTM Dec 2025$848K ———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding EVH) $53.97M+16.2%+6.3%43.0%

Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue907.96M1.35B1.96B2.55B1.88B
Cost of Revenue657.55M1.04B1.5B2.19B1.59B
Gross Profit250.41M316.58M460.47M367.35M284.03M
Gross Margin27.6%23.4%23.4%14.4%15.1%
Research & Development027M000
Selling, General & Admin219.5M269.27M358.11M263.05M288.47M
Operating Expenses292.82M312.94M531.68M407.84M288.47M
Depreciation & Amortization60.04M90.25M123.42M123.17M115.85M
EBITDA55.66M43.75M(24.79M)84.85M(361.31M)
EBITDA Margin6.1%3.2%-1.3%3.3%-19.3%
Operating Income(42.41M)3.64M(71.21M)(40.49M)(4.44M)
Operating Margin-4.7%0.3%-3.6%-1.6%-0.2%
Interest Income407K1.37M5.26M5.54M4.19M
Interest Expense25.43M15.57M54.21M24.72M57.47M
Other Income / Expenses12.61M(65.72M)(131.19M)(22.55M)(530.2M)
Income Before Tax(29.8M)(62.08M)(202.41M)(63.04M)(534.64M)
Pre-Tax Margin-3.3%-4.6%-10.3%-2.5%-28.5%
Income Tax Expense483K(43.38M)(89.37M)(1.41M)(126K)
Net Income(37.6M)(19.16M)(113.04M)(61.62M)(534.51M)
Net Margin-4.1%-1.4%-5.8%-2.4%-28.5%
EPS (Basic)(0.36)(0.20)(1.28)(0.81)(5.07)
EPS (Diluted)(0.36)(0.20)(1.28)(0.81)(5.07)
Weighted Avg Shares86.07M93.7M111.25M114.68M114.21M
Weighted Avg Shares (Diluted)86.07M93.7M111.25M114.68M114.21M

Evolent Health, Inc.

NYSE:EVH

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.